7th Aug 2019 11:47
(Alliance News) - Evgen Pharma PLC on Wednesday said it has secured further intellectual property rights in Europe for SFX-01.
The drug development company, focused on breast cancer and subarachnoid haemorrhages, said the newly granted patent covers "a composition comprising a complex of sulforaphane and alpha-cyclodextrin".
Composition-of-matter patents have already been granted in the US and "other territories", Evgen noted, with patents in Europe, the US and "other territories", relating to the method of production, have also been secured.
Exclusive worldwide rights to the patent are held by Evgen, it said, under the terms of a licence agreement with PharmAgra Labs Inc, the US laboratory that invented SFX-01.
"This patent has broad claims relating to the composition of the novel drug substance, SFX-01, and as such represents a material development for the company," said Chief Executive Steve Franklin.
"The overall intellectual property position around SFX-01 and novel analogues has matured into an impressive patent estate, asserting our exclusive position around this new class of pharmaceutical," added Franklin.
Evgen shares were trading 2.9% lower on Wednesday in London at 16.88 pence each.
Related Shares:
EVG.L